Orphan Drugs

Showing 7 posts of 7 posts found.


Global orphan and rare dermatology market set to exceed $6 billion by 2024

August 31, 2018
Medical Communications Orphan Drugs, analysis, dermatology, market reports, rare diseases

The global orphan and rare dermatology premium products market is expected to grow rapidly in the next half a decade …


FDA approves RNA therapy for rare genetic disease

August 13, 2018
Sales and Marketing FDA, Onpattro, Orphan Drugs, RNA, rare diseases

The US Food and Drug Administration has approved the RNA-based therapy Onpattro, for the treatment of the rare genetic disease …

TREND: Rare disease, cancer drugs will drive pharma M&A’s, growth

March 29, 2016
Manufacturing and Production, Research and Development, Sales and Marketing M&A, MA, Orphan Drugs, cancer drugs

Moody’s Investor Service lowered its growth outlook for the global pharma sector but maintained the mergers and acquisitions in the …


EMA recommends AZ/Acerta drug for orphan status in three indications

February 25, 2016
Research and Development AstraZeneca, EMA, Orphan Drugs

The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended AstraZeneca and Acerta’s acalabrutinib (ACP-196) for designation …

Novartis’ myelofibrosis treatment approved in Europe

August 28, 2012
Sales and Marketing Incyte, Jakavi, Novartis, Orphan Drugs, myelofibrosis

Novartis’ Jakavi, a new treatment for patients with myelofibrosis has been approved in Europe. The drug was co-developed with Incyte, …

First idiopathic pulmonary fibrosis drug approved

March 4, 2011
Sales and Marketing Esbriet, IPF, InterMune, Orphan Drugs, idiopathic pulmonary fibrosis, orphan drug

The first ever treatment for the potentially fatal lung disease idiopathic pulmonary fibrosis (IPF) has been approved in the EU. …

Genzyme again snubs suitor Sanofi

November 10, 2010
Research and Development, Sales and Marketing Campath, Chris Viehbacher, Genzyme, Henri Termeer, Orphan Drugs, Plavix, Sanofi, Sanofi-Aventis, manufacturing compliance

Genzyme has once again snubbed Sanofi-Aventis as the French pharma firm continues its pursuit of the beleaguered biotech company. Henri …

Latest content